13th Biosimilars Congregation 2019
Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars
11th & 12th June 2019, Pestana Chelsea Bridge Hotel, London, UK
13th Biosimilars Congregation 2019 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.
KEY SPEAKERS:
- SUE NAEYAERT, Global Head Government Affairs, Policy & Pharmaceconomics, Fresenius Kabi SwissBioSim
- SHU-YI SU, Statistical Scientist, Novartis
- IAN HENSHAW, VP, Global Head of Biosimilar Business Unit, Biogen
- MAGNUS BODIN, Director, Market Access Biosimilars, Biogen
- CHRISTIAN AGBOTON, Sr Global Brand Medical Director - Global Medical Affairs, Takeda
- JOSEPH DUNFORD, European Biosimilar Franchise Manager, Accord Healthcare
- VICTOR SASTRE, Senior MSL , Amgen Biosimilars, (Board Member MSL Society Advisory)
- FREDRIK SUNDBERG, Director Strategic Customer Relations, GE Healthcare
- HANMANT BARKATE, Vice President & Head Medical Services, (India, MEA), Glenmark (India)
- JOSEPH SALAMEH, Medical Lead, Alnylam Pharmaceuticals
- STEINAR MADSEN, Medical Director, Norwegian Medicines Agency
- LOUIS BOON, CSO, Bioceros
- LIZ POLLITT, Director, BPCRCS
- LENNEKE DE WINTER, USP Director, Bioceros
- CORNELIA ULM, VP Regulatory Affairs Biosimilars, Biotec Regulatory Consulting
- KARL DAVISON, Business Development Officer, NIHR Clinical Research Network
- JUSTIN STEBBING, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College Healthcare NHS Trust
- MARIE MANLEY, Partner, Head of the UK Life Sciences Practice, Sidley Austin
- JACQUELINE MULRYNE, Counsel, Arnold & Porter LLP
KEY THEMES:
- Strategies for market access and expansion by identifying key changes and future projections
- Consequences of Brexit on Biosimilars
- Current Challenges and Opportunities for future- Strategies in developing Biosimilars
- A Clinician ́s Guide to Biosimilars in Oncology: understanding the Science of Extrapolation and Interchangeability
- Biosimilars – Pricing & Market access - Bringing it faster into market
- GMP, GCP, QC & R&D
- Current challenges and opportunities - strategies to develop Biosimilars
- Payer perspective on biológics and Biosimilars
- Biosimilar Interchangeability: The newest regulation
- Biosimilar - Physicians and Patients perspective
- CMC, Preclinical and clinical considerations for Biosimilars and Follow-on Biologics
- Impact of Technology
- Commercial landscape & market access for Biosimilars: Predicts to prepare for a suceesful tomorrow
- Hear case studies on biosimilars drug development from pre-clinical to clinical and the various testing required such as immunogenicity and bio-similarity tests
- Research-based industry Biosimilar strategies
- Considerations for the analytical similarity assessments when designing a Biosimilar development program
- Determining the right investments & potential returns from Biosimilars
- Latest developments in regulation to increase speed of entry and compliance
- Future of next generation biosimilars
- Be part of a major networking opportunity
WHO SHOULD ATTEND:-
CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs, Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing
CONFERENCE SPONSORSHIP:
Sponsor, Exhibition Stall (Booth) and a paid Speaker Slots are also available
We also have some sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit, and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.
CONFERENCE REGISTRATION:
- Introductory Offer - 3 delegate places for the price of 2 - A huge saving of £750 - (Limited seats left)
- Super Early Discount (Valid Till 1st April 2019): (£750 + VAT per delegate)
- Early Discount (2nd April 2019 - 12th May 2019): (£950 + VAT per delegate)
- Standard Registration (13th May 2019 Onwards): (£1150 + VAT per delegate)
Get more from the event, enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
